Hoffmann-La Roche Inc. received USPTO publication for patent application US20260091062A1 covering combination therapy using recombinant Fc domain-IL-2 variant polypeptides with membrane-anchored antigen binding polypeptides for cancer prevention and treatment. The application claims compositions and methods classified under CPC codes including A61K 35/17, C07K 14/55, and C07K 14/705. Inventors include Diana Darowski, Stephan Gasser, Christian Klein, Simone Lang, and Dario Venetz.

This patent publication is informational only and does not impose compliance requirements. Pharmaceutical companies developing IL-2 based cancer immunotherapies should review the claims to assess potential freedom-to-operate considerations. No action is required unless the entity is actively developing competing IL-2 variant therapies that may fall within the claimed combination framework.